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Zusammenfassung
Hintergrund: Obwohl mesenteriale Veränderungen be-
kanntermaßen mit Non-Hodgkin-Lymphomen (NHL) as-
soziiert sind, ist die Häufigkeit und prognostische Bedeu-
tung dieser mesenterialen Veränderungen unbekannt.
Patienten und Methoden: 120 zwischen Januar 1996 und
Dezember 2001 in Behandlung stehende NHL-Patienten
wurden retrospektiv auf das Vorliegen mesenterialer Ver-
änderungen untersucht. Computertomographie (CT)-Kri-
terien umfassten noduläre oder diffuse, mesenteriale 
Infiltrate, mit konsekutiven Signalalterationen des me-
senterialen Fettgewebes. Ergebnisse: Bei 21 Patienten
(17,5%) fanden sich radiologisch mesenteriale Verände-
rungen zum Zeitpunkt der NHL-Diagnose. Mesenteriale
Veränderungen waren signifikant assoziiert mit mesent-
erialer Lymphadenopathie (p = 0,01). Bei rund 50% der
Patienten konnten die mesenterialen Veränderungen
nicht durch direkten mesenterialen Tumorbefall oder
lymphatische Obstruktion erklärt werden. Patienten mit
Nachweis mesenterialer Veränderungen bei Diagnose-
stellung der Grundkrankheit (NHL) hatten ein nichtsignifi-
kant höheres 4-Jahresüberleben verglichen mit Patien-
ten ohne solche Veränderungen (79 vs. 43%, p = 0,11).
Der International Prognostic Index (IPI)-Quotient war der
einzige unabhängige prognostische Faktor bezüglich Ge-
samtüberleben in der multivariaten Analyse. Schlussfol-
gerung: Diese retrospektive Studie fand eine hohe Präva-
lenz mesenterialer Veränderungen in Patienten mit ver-
schiedenen NHL-Entitäten. Der diagnostische und pro-
gnostische Wert mesenterialer Veränderungen sollte in
prospektiven Studien untersucht werden.
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Summary
Background: Mesenteric alterations are associated with
non-Hodgkin’s lymphoma (NHL), but the frequency and
prognostic value of mesenteric alterations are unknown
in patients with NHL. Patients and Methods: We retro-
spectively screened 120 patients that were treated for
NHL between January 1996 and December 2001 for the
presence of mesenteric alterations, defined on computed
tomography (CT) scans as nodular or diffuse infiltration
of the abdominal mesentery with increased density of
mesenteric fat. Results: 21 patients (17.5%) had radiolog-
ical findings of mesenteric alterations at the time of the
initial NHL diagnosis. Mesenteric alterations were signif-
icantly associated with mesenteric lymphadenopathy (p
= 0.01). In about 50% of the patients, mesenteric alter-
ations could not be explained by direct mesenteric tu-
mour invasion or overt lymphatic obstruction. Patients
with initial findings of mesenteric alterations tended to
have a better 4-year survival as compared to patients
without such findings (79 vs. 43%, p = 0.11). The Interna-
tional Prognostic Index (IPI) score was the only indepen-
dent predictor of survival in the multivariate analysis.
Conclusion: This retrospective screening study found a
moderate prevalence of mesenteric alterations in pa-
tients with various subtypes of NHL. The diagnostic and
prognostic value of mesenteric alterations should be fur-
ther assessed in prospective studies. 
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The annual incidence rate of non-Hodgkin’s lymphoma
(NHL) from 1995 to 1999 was 19.1 cases per 100,000 persons,
as estimated from the Surveillance, Epidemiology, and End
Results (SEER) Program of the National Cancer Institute [1].
The overall incidence rate is 23.6 per 100,000 for males and
15.4 per 100,000 for females, and increases with age [1]. While
the majority of NHL cases arise in lymph nodes, primary ex-
tranodal disease is found in 20–30% [2, 3]. The current World
Health Organisation (WHO) classification recognises 2 cate-
gories of NHL – B-cell neoplasms and T-/natural killer (NK)
cell neoplasms – both being stratified into immature precursor
lymphoblastic lymphomas/leukaemias and mature peripheral
neoplasms [4]. The International Prognostic Index (IPI) sepa-
rates 4 risk groups of patients with diffuse large B-cell lym-
phoma (DLBCL) [5] or low-grade lymphoma [6], and is wide-
ly used for therapeutic stratification of individual patients and
the design of clinical trials. C-reactive protein (CRP) serum
level was reported to have some prognostic value in a small
group of patients with various entities of NHL [7], but the IPI
stratification reveals the most useful prognosticator in patients
with NHL so far. 
Alterations of the abdominal mesenteries have recently been
found to be associated with NHL in a substantial part of these
patients [8–10]. Daskalogiannaki et al. [9] found mesenteric al-
terations in 0.6% of a general population with abdominal
symptoms, where it was associated with malignancy in 69% of
cases, mostly extraabdominal NHL (in 12% of patients),
breast cancer (10%), and colorectal cancer (10%). The ab-
dominal mesenteries are primarily composed of fat, through
which run the major arteries, veins, and lymphatic vessels of
the bowel. An alteration in the density of the mesenteric fat is
often the principal evidence of underlying mesenteric and
bowel disease. Mindelzun et al. [8] have coined the term of
‘misty mesentery’ to describe the appearance of altered
mesenteric fat on computed tomography (CT) [8]. Mesenteric
abnormalities as diagnosed by CT scans have further been de-
scribed as ‘primary (idiopathic) mesenteritis’ [11], ‘mesenteric
lipodystrophy’ [12, 13], ‘retractile mesenteritis’ [14–17], ‘in-
traabdominal panniculitis’ [18], ‘mesenteric panniculitis’ [9, 19,
20], or ‘sclerosing mesenteritis’ [21] among others. With infil-
tration of the mesentery by fluid or cells, the mean density of
mesenteric fat increases to –28 to –85 Hounsfield Units, and
the mesenteric arteries and veins often lose their sharp inter-
faces [9]. Depending on the nature and extent of the infiltra-
tion, mesenteric vessels may be either completely or partially
effaced. Etiologically, mesenteric alterations may be caused by
mesenteric oedema (due to hypoalbuminaemia, cirrhosis,
nephrosis, heart failure, mesenteric artery and vein thrombo-
sis, vasculitis, and trauma), lymphoedema (due to congenital
abnormalities, inflammation, neoplasms, surgery, and radio-
therapy), inflammation (primarily pancreatitis), haemorrhage
and trauma, or neoplasms. The most common tumour involv-
ing the mesentery is NHL that typically presents with bulky
adenopathy [8]. However, NHL-associated mesenteric alter-
ations may more readily be recognized after therapy-induced
tumour size reduction [8]. In a series of 53 patients with
mesenteric lipodystrophy by Kipfer et al. [12], 8 patients were
found to have NHL. The diagnosis of mesenteric alterations
may precede NHL, as was the case in 2 of 27 patients with
‘mesenteric panniculitis’ [20]. In the present study, the authors
retrospectively assessed the frequency and prognostic value of




All consecutive patients treated for NHL at the Department of Oncology
of the Kantonsspital St. Gallen, Switzerland, between January 1996 and
December 2001 were included in a retrospective analysis. The study popu-
lation included patients with prevalent NHL (diagnosis before 1996) and
incident NHL (diagnosis between January 1996 and December 2001).
Clinical data were extracted from patient and electronic files, and abdom-
inal CT scans were reviewed for the presence of mesenteric alterations.
Histological diagnoses were retrospectively adapted to the current WHO
classification [4]. Patients with secondary malignancies were excluded.
Clinical and laboratory parameters such as stage, histology, and disease lo-
cation, B-symptoms, ECOG performance status, weight, abdominal
surgery, comorbidity, haematology, and blood chemistry were assessed at
the time of initial NHL diagnosis. Stage of disease according to the Ann
Arbor classification [22] and IPI score [5] were assessed from individual
patient data. Time and modality of treatment (chemotherapy, radiothera-
py, surgery), treatment response, and clinical outcome (i.e. overall sur-
vival) were assessed in all patients. 
International Prognostic Index
As detailed by the International Non-Hodgkin’s Lymphoma Prognostic
Factors Project [5], variables used in the IPI are age (< 60 vs. > 60 years),
performance status (ECOG 0 or 1 vs. 2–4), Ann Arbor stage (I or II vs. III
or IV), serum lactate dehydrogenase (LDH) level (normal vs. elevated),
and number of extranodal sites. Patients with no or 1 unfavourable vari-
able were considered to be at low risk, those with 2 to be at low-interme-
diate risk, those with 3 to be at high-intermediate risk, and those with 4 or
5 unfavourable variables to be at high risk.
CT Scans
Hardcopies of 825 CT scans were reviewed retrospectively, including 736
abdominopelvic and 89 abdominal CT scans in a total of 120 patients. Ra-
diological examinations had been performed with different types of
whole-body CT scans. One radiologist reviewed all scans with special em-
phasis towards the diagnosis of infradiaphragmatic lymph node involve-
ment, involvement of the liver or the spleen, and the presence of mesen-
teric alterations. Mesenteric alteration was defined as a mass-like focal
area of increased nodular, linear, or irregular attenuation within the
mesenteric fat, surrounded by a hyperattenuating pseudocapsule. The so-
called fat ring or fatty halo sign, which means preservation of the fat near-
est to the mesenteric vessels within the observed mass, was not mandatory
for the diagnosis of mesenteric alterations. Accordingly, CT scans were
classified as either presenting or not presenting mesenteric alterations.
Data Analysis
Statistical analysis was performed using the statistical package SAS for
windows, version 8.2 (SAS Institute, Cary, NC, USA). Categorical vari-
Onkologie 2008;31:514–519Mesenteric Alterations in NHL 515
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Parameter All patients Patients with MA Patients without MA p 
median (range) median (range) median (range) value
Age, years 58 (15.5–87.8) 54.4 (20.2–70.9) 58.6 (15.5–87.8) > 0.05
Male sex, % 60 61.9 59.6 > 0.05
Mesenteric lymphopathy, % 25 47.6 20.2 0.013
Abdominal lymphopathy, % 47.5 61.9 44.4 > 0.05
IPIa 2 (0–4) 1.5 (0–3) 2 (0–4) > 0.05
Performance status 0 (0–3) 0 (0–3) 0 (0–2) > 0.05
BMI, kg/m2 24.1 (16.4–37.3) 23.2 (17.7–29.6) 24.3 (16.4–37.3) > 0.05
Hemoglobin, g/l 130 (44–167) 139 (69–167) 130 (44–165) > 0.05
Leukocytes, 109/l 6.8 (2.0–52.9) 6.7 (2.0–14.4) 6.8 (2.0–52.9) > 0.05
Thrombocytes, 109/l 237 (5–664) 242 (7–422) 236 (5–664) > 0.05
LDH, U/l 455 (132–11,710) 438 (231–859) 462 (132–11,710) > 0.05
Albumin, g/l 43 (30–54) 45 (30–51) 43 (30–54) > 0.05
Creatinine clearanceb, ml/min 62 (21–114) 63 (40–104) 61 (21–114) > 0.05
ASAT, U/l 24 (10–263) 28 (15–61) 23 (10–263) > 0.05
ALAT, U/l 18 (7–342) 24 (13–67) 18 (7–342) > 0.05
CRP, mg/l 9 (0–269) 9 (0–113) 9 (0–269) > 0.05
β2 microglobulin, mg/l 4.6 (2.4–7.9) 4.5 (2.5–7.4) 4.6 (2.4–7.9) > 0.05
aIPI 0 and 1 = low risk, 2 = low-intermediate risk, 3 = high-intermediate, 4 and 5 = high risk.
bCreatinine clearance according to the Cockcroft-Gault formula: (140-age) × weight/serum creatinine, with a 15% 
correction for females.
MA = Mesenteric alterations (as defined in the Methods section); IPI = International Prognostic Index; BMI = body mass
index; LDH = lactate dehydrogenase; ASAT = aspartate aminotransferase; ALAT = alanine aminotransferase; 
CRP = C-reactive protein.
Table 1. Patient
characteristics
Subtypes of NHL (WHO classification 2001) All MA at initial MA during 
patientsa diagnosis follow-up 
(Capsule-like (Capsule-like
structure) structure)
B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma 8 1 (1) 2 (1)
Hairy cell leukaemia 1 1 (1) 1 (1)
Plasma cell neoplasm 1 0 0
Extranodal marginal zone B-cell lymphoma (MALT lymphoma) 3 0 0
Follicular lymphoma, grade I/II 28 7 (4) 16 (12)
Follicular lymphoma, grade III 8 0 3 (1)
Follicular lymphoma, undefined grading 2 0 0
Mantle cell lymphoma 9 1 (1) 1 (1)
Diffuse large B-cell lymphoma 26 3 (2) 7 (4)
Burkitt’s lymphoma/leukaemia 4 1 (0) 1 (0)
B-cell lymphoma, unclassifiable 4 1 (1) 2 (2)
Precursor T-lymphoblastic leukaemia/lymphoma 1 0 0
Peripheral T-cell lymphoma, unspecified 6 3 (0) 4 (2)
Anaplastic large cell lymphoma 3 1 (0) 1 (1)
Lymphoid neoplasm/lymphoma, unclassifiable 1 0 0
B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma 
and diffuse large B-cell lymphoma 2 0 0
Extranodal marginal zone B-cell lymphoma and diffuse large  
B-cell lymphoma 2 0 1 (0)
Follicular lymphoma grade I/II and diffuse large B-cell lymphoma 2 1 (1) 2 (2)
Follicular lymphoma grade III and diffuse large B-cell lymphoma 5 1 (0) 3 (1)
Follicular lymphoma and diffuse large B-cell lymphoma 1 0 1 (0)
Angioimmunoblastic T-cell lymphoma 0 0 0
aHistology was not evaluable in 2 patients.
NHL = Non-Hodgkin’s lymphoma.
































   
   
   
   





















ables were compared using Fisher’s exact test. Continuous variables were
compared using Student’s t-test or Wilcoxon rank-sum test according to
normality assumptions. Univariate survival analysis was done using the
Kaplan-Meier technique and the log rank test on the original data set. In
order to account for a possible lead-time bias as to the retrospective inclu-
sion of NHL patients with an initial diagnosis before 1996, the origin of
survival calculations was reset to 1996 for this group of patients. For mul-
tivariate analysis, the problem of missing covariates was addressed by a
conservative imputation technique. If a continuous variable was unavail-
able in more than one third of cases, it was not further processed; other-
wise, the median was substituted for missing values. No other transforma-
tions or interaction terms were applied. Subsequently, multivariate step-
wise Cox regression was used to develop a parsimonious model. A signifi-
cance level of 0.1 was requested for model entry, and a level of 0.05 to
remain in the model. Covariates that were contained in disease stage
(Ann Arbor) or IPI score were not separately modelled in the multivari-
ate analysis to avoid collinearity. The final model was then recalculated
using the original data set, and a bootstrap procedure was performed for
validation purposes. 
Results
120 patients were included in this study. NHL was diagnosed
before 1996 in 33 patients and thereafter in 87 patients (time
frame: December 1983 to March 2001). Median follow-up was
2.15 years (8 days to 17.8 years). Table 1 summarises the pa-
tient characteristics. IPI could be assessed in 92 patients, and
was lacking in the remaining patients (including 15 patients
with follicular lymphoma and 3 patients with DLBCL). Ac-
cording to the IPI score, 36 patients (39%) were at low risk, 27
(29%) at low-intermediate risk, 24 (26%) at high-intermediate
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Fig 1. A Extensive retroperitoneal (a) and
mesenterial (b) lymphoma with additional
mesenteric alterations (higher density compared
to surrounding fat tissue, arrows) (native CT
scan left, intravenous (iv) contrast right). 
B Extensive retroperitoneal (a) and mesenterial
(b) lymphoma (iv contrast left) with near
 complete remission and remaining mesenteric
alterations (arrows) (iv contrast right). 
C Mesenteric alterations in a patient with
 extraabdominal lymphoma (arrows) (native 
CT scan left, iv contrast right). D Mesenteric 
alterations in a patient with adenocarcinoma of
the colon (native CT scan left, iv contrast right).


























   
   
   
   





















Fig 3. Presence of mesenteric alterations per IPI risk group (p value for
trend > 0.05). IPI 0 and 1 = low risk, 2 = low-intermediate risk, 3 = high-in-
termediate, 4 and 5 = high risk.
tion was found between lymphoma subtypes and mesenteric
alterations. NHL subtypes according to the current WHO
classification are outlined in table 2.
In the univariate analysis, elevated C-reactive protein (CRP),
gamma glutamyl transferase (GGT) or LDH, lower creatinine
clearance, abnormal leukocyte or thrombocyte counts, and
higher IPI scores were significant predictors of worse overall
survival (table 3, fig. 4). However, only the IPI score was an in-
dependent predictor of overall survival in the multivariate
analysis and after adjustment for gender and year of diagnosis,
with a hazard ratio of 2.2 by each unit increase of IPI (95%
confidence interval (CI) 1.5–3.3). 
Discussion
So far, a single systematic screening study assessed 7,620 ab-
dominal CT scans from symptomatic patients [9]. Mesenteric
alterations were found in 49 patients (0.6%), and an associa-
tion with NHL was found in 6 of these 49 patients (12%). As
to our knowledge, this is the first systematic study on mesen-
teric alterations in NHL patients. This retrospective study
found mesenteric alterations in a moderate 22 of 120 patients
(17.5%) at the time of first diagnosis of lymphoma, and in 45
of 120 patients (37.5%) at any point in time. However, as no
histological confirmation of suspected mesenteric lymphoma
is available, the association between mesenteric alterations
and NHL needs further study. In the presented study, mesen-
teric alterations were diagnosed in 24 of 120 patients (20%)
on follow-up examinations, including 10 patients with initial
bulky disease. Gross initial tumour load might have made the
initial diagnosis of mesenteric alterations impossible in these
patients, while these alterations became radiologically visible
after tumour shrinkage. In a general patient population, the
differential diagnosis of mesenteric alterations includes a wide
range of diseases, such as mesenteric oedema by hypoalbu-
minaemia, heart failure, lymphoedema, inflammation by pan-
creatitis, haemorrhage and trauma, or neoplasms [8]. The
pathophysiologic mechanism underlying mesenteric abnor-
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risk, and 5 (5%) at high risk. At the time of first diagnosis, 21
of 120 patients (17.5%) had findings consistent with mesen-
teric alterations (fig. 1). Another 24 patients (20%) had radio-
logical findings of mesenteric alterations on subsequent CT
scans. Ten of these 24 patients (42%) had large mesenterial
tumour burden at first diagnosis, which made the diagnosis of
mesenteric alterations at first radiological assessment impossi-
ble. Mesenteric alterations with capsule-like structures were
found in 11 patients (53% of all patients with mesenteric al-
terations) at the time of first diagnosis, and in 28 patients at
follow-up (63% of all patients with mesenteric alterations at
follow-up). Ten of the 21 patients (48%) with initial mesen-
teric alterations had enlarged mesenterial lymph nodes, but
only 20 of the 99 patients (20%) without initial mesenteric al-
terations had enlarged mesenterial lymph nodes (p = 0.013 for
the difference). 
Patients with an initial diagnosis of mesenteric alterations
showed a trend towards increased overall survival as com-
pared to patients without these findings (4-year survival 79 vs.
43%, p = 0.11) (fig. 2). No correlation was found between IPI
scores and radiological findings of mesenteric alterations at
initial diagnosis (fig. 3). Furthermore, no significant correla-
Fig 2. Kaplan-Meier
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malities in lymphoma patients has not been studied systemati-
cally, but neoplastic infiltration of the mesentery and lym-
phoedema secondary to obstruction of the lymphatics may be
most likely. No correlation with lymphoma subtypes was
found in the presented study, but mesenteric alterations were
frequently found in the small subgroup of patients with pe-
ripheral T-cell lymphoma (3 out of 6 patients). Although pa-
tients with mesenteric alterations on initial CT scans had a
non-significant increase in mean overall survival (fig. 2), inter-
pretation of this finding remains hypothetical. Mesenteric al-
terations might be a surrogate for active immune response to
underlying lymphoma, which in turn could result in improved
clinical outcome. 
Increased CRP levels and lower creatinine clearance were sig-
nificantly associated with increased mortality in the univariate
model (table 3), but not in the multivariate model. CRP has
previously been described as a prognostic marker in NHL by
Legouffe et al. [7]. Physiologically, CRP synthesis is boosted by
IL-6 which in turn plays a central role in normal B-cell matura-
tion and proliferation of some B-cell neoplasms [23]. In the lat-
ter study, CRP was significantly correlated with IL-6 and LDH
levels. This collinearity between CRP and LDH may account
for the lack of an independent prognostic value of CRP in ad-
dition to the IPI score. Similarly, impaired renal function was
no longer significant in a multivariable survival model. Howev-
er, our study did not have the power to exclude a milder asso-
ciation between decreased renal function and mortality.
In conclusion, this retrospective screening study found a mod-
erate prevalence of mesenteric alterations in patients with var-
ious subtypes of NHL. In about 50% of the patients, these
findings could not be explained by direct mesenteric tumour
invasion or overt lymphatic obstruction. Further studies
should clarify the diagnostic value of mesenteric alterations
for underlying lymphoma. 
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Table 3. Significant univariate prognostic factors for overall survival




CRP > 8 mg/l 68 4.8 1.6–14.4 0.005
γ-GT > 50 U/l 91 3.2 1.4–7.2 0.004
Lower clearance (by 10 ml/min) 92 1.2 1.0–1.5 0.033
LDH > 450 U/l 93 2.8 1.2–6.1 0.01
Abnormal leukocytes 91 3.3 1.5–7.1 0.002
Abnormal thrombocytes 91 2.7 1.3–5.9 0.01
Higher IPI (by 1 unit) 120 2.3 1.5–3.3 <0.0001
HR = Hazard ratio; CI = confidence interval; CRP = C-reactive protein;
GT = glutamyltransferase; LDH = lactate dehydrogenase; IPI = Interna-
tional Prognostic Index.
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